Skip Navigation LinksHome > March 2011 - Volume 111 - Issue 3 > New Antibiotic for MRSA and Pneumonia
AJN, American Journal of Nursing:
doi: 10.1097/10.1097/01.NAJ.0000395236.76228.89
Drug Watch

New Antibiotic for MRSA and Pneumonia

Aschenbrenner, Diane S. MS, RN

Free Access
Article Outline
Collapse Box

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

Collapse Box

Abstract

* A new cephalosporin, ceftaroline fosamil (Teflaro), has been approved to treat acute bacterial skin infections caused by methicillin-resistant Staphylococcus aureus, as well as serious community-acquired bacterial pneumonia requiring hospitalization.

* Ceftaroline fosamil is administered as an IV infusion.

Ceftaroline fosamil (Teflaro) is a newly approved cephalosporin that's effective in the treatment of acute bacterial skin infections caused by methicillin-resistant Staphylococcus aureus and community-acquired bacterial pneumonia severe enough to require hospitalization. Ceftaroline must be administered as an IV infusion.

Clinical trials compared the drug with standard therapy: in patients with community-acquired bacterial pneumonia, ceftaroline was compared with IV infusions of ceftriaxone, another cephalosporin; in patients with acute bacterial skin and skin-structure infections, it was compared with a combination of vancomycin and aztreonam, a monobactam. For both types of infection, ceftaroline was found to be as effective as the standard therapy. The most common adverse effects were diarrhea, nausea, and rash.

Nurses should be aware of this new cephalosporin. For more on the drug's approval, go to http://bit.ly/bbtT3C.

© 2011 Lippincott Williams & Wilkins, Inc.

Login